Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

p>

"It's impressive to see this response to LBH589 in patients, many of whom have received multiple courses of chemotherapy," said Anna Sureda, MD, Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. "The responses suggest LBH589, which has a very different mechanism of action than chemotherapy, has the potential to become a valuable treatment option for these patients."

LBH589 is an oral pan-deacetylase (DAC) inhibitor, which targets changes in gene function (also known as epigenetic regulation) that regulate processes in the development of cancer, including proliferation and survival of Hodgkin lymphoma cells in laboratory studies(5). A Phase III clinical trial (PATH: PAnobinostat Trial in Hodgkin's lymphoma) has begun enrollment, investigating the drug as a maintenance therapy following autologous stem cell transplant in patients with Hodgkin lymphoma who have an increased risk for relapse(6). The clinical development program for LBH589 also includes an ongoing Phase III clinical trial in multiple myeloma and early-stage trials in acute myeloid leukemia and myelodysplastic syndromes.

"These positive findings for LBH589 are encouraging for many Hodgkin lymphoma patients who currently lack effective treatments," said Alessandro Riva, Global Head, Oncology Development & Medical Affairs, Novartis Oncology. "Patients who are not cured by autologous stem cell transplant and have stopped responding to chemotherapy have an urgent unmet medical need for novel therapeutic options. We are committed to the rapid development of this promising compound for these patients."

Hodgkin lymphoma is most commonly diagnosed in teenagers and adults between the ages of 15 and 35 and in adults over 50(7). It is the third most common cancer in people under the age of 20(8). Treatment options for Hodgkin lymphoma typically involve an initial round of combination chemotherapy, but standard frontline treatments do not lead to lon
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... -- Pfenex Inc. (NYSE MKT: PFNX) today announced the IND ... and is now open and that this program has ... and Human Services (HHS), through the Biomedical Advanced Research ... pleased to have the IND now active for our ... in our company,s partnership with BARDA as we continue ...
(Date:12/19/2014)... 19, 2014  Newport Corporation (NASDAQ: ... has joined the company,s Board of Directors.  Dr. ... a director of Evans Analytical Group, a leading ... analytical services to companies in a wide range ... Evans Analytical Group, Dr. Kadia spent nine years ...
(Date:12/19/2014)... Dec. 19, 2014 In today,s increasingly ... web presence to reflect the needs of a ... must meet the needs of key stakeholders while ... According to recent research by benchmarking ... the participating companies averaged more than $100,000 in ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Building a Best-in-Class Pharma Global Brand Website 2
... , BUDAPEST, Hungary , ... Pfizer Globally Licenses ChemAxon,s Platform For Markush Structure,Searching And Enumeration ... of cheminformatics software for the life,sciences industry has entered into ... functionality for global,development and deployment within Pfizer,s global R&D facilities. ...
... , , , ... The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) ... sclerosis (MS). In clinical trials, patients treated with Ampyra had ... (placebo). This is the first drug approved for this use. ...
Cached Medicine Technology:FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis 2
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... 2014 The Bob Woodruff Foundation ... invested more than $5 million in programs and ... their families. , This includes $1.3 million in ... helping with: veteran entrepreneurship; community impact; vocational training; ... severely injured veterans. , “The needs of those ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Give a ... season, the gift of health and vitality. , For ... its three top-selling anti-aging formulas in special Holiday Wellness ... rush delivery. , Each bottle contains cutting-edge, proven ... that don't work as well as we age. ...
(Date:12/22/2014)... York NY (PRWEB) December 22, 2014 ... that a federal panel of judges has granted a ... in the U.S. District Court, Eastern District of ... issued an order on December 12 to transfer over ... in 22 districts to the Louisiana court for consolidation ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
... separated at the time of diagnosis do not live as ... the conclusion of a new study to be published in ... peer-reviewed journal of the American Cancer Society. The authors of ... with marital separation may compromise an individual,s immune system and ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Pulmonary Fibrosis is not much better than a death ... is less than three years. But researchers at ... a novel gene utilizing genetic and pharmacologic strategies was ... be developed for future testing in humans. The ...
... works best , SUNDAY, Aug. 23 (HealthDay News) -- Medics ... activity when trying to save a person who,s had a ... defibrillation to restart the heart. , But studies now show ... as ordinary cardiopulmonary resuscitation, or CPR. And what,s more, those ...
... ... facility, positioning the company to support defense-related semiconductor manufacturing and development programs. , ... Cherry Hill, NJ (PRWEB) ... Arms Regulations) registered for its Cherry Hill, New Jersey manufacturing facility. ITAR regulates the ...
... root, study finds , FRIDAY, Aug. 21 (HealthDay News) -- ... before they take root in the brain. , That,s the ... rats -- assuming the findings can be applied to humans, ... of Rio Grande do Sul, Brazil, with colleagues at the ...
Cached Medicine News:Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:New technique can help diagnose mesothelioma 2Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2Health News:It's Back to Basics to Save a Life 2Health News:It's Back to Basics to Save a Life 3Health News:International Micro Industries (IMI) is ITAR Registered 2Health News:Dopamine Lets Bad Experiences Linger 2Health News:Dopamine Lets Bad Experiences Linger 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
Medicine Products: